Theragenics® Regains Compliance with NYSE Listing Standards
6/5/2009 9:55:20 AM
BUFORD, Ga.--(BUSINESS WIRE)--Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced it was notified by the New York Stock Exchange (the “NYSE”) that the Company is in compliance with the NYSE continued listing requirement pertaining to market capitalization and stockholders’ equity, as modified by the NYSE. This continued listing criterion, as modified, requires a company to maintain shareholders’ equity of at least $50 million if the company’s average market capitalization over a 30-day trading period is less than $50 million. Previously, the numeric thresholds in this requirement were $75 million. This modification is effective through October 31, 2009. The NYSE has stated that it anticipates a subsequent rule filing prior to October 31, 2009 to make this change a permanent continued listing standard. As of April 5, 2009, the completion of the Company’s most recent quarterly period, its stockholders’ equity totaled $74.9 million. As previously announced, Theragenics was notified by the NYSE on March 18, 2009 that it had fallen below compliance with the continued listing standards, as the Company’s stockholders’ equity, shareholders’ equity and market capitalization over 30 trading days was below $75 million.
comments powered by